Oral Cancer Treatment Market Expected to Reach $2.7 Billion by 2030 | Current Trends and Industry Analysis

Oral Cancer Treatment Market was valued at $1.7 billion in 2020 and is projected to reach $2.7 billion by 2030 registering a CAGR of 4.80% from 2021 to 2030. Oral cancers are part of a group of cancers commonly referred to as head and neck cancers, and of all head and neck cancers, they comprise about 85% of that category. Furthermore, oral cancer accounts for approximately three 3% of all cancers diagnosed annually in the U.S, or about 53,000 new cases each year. In addition, oral cancer most often occurs in people over the age of 40 and affects more than twice as many men as women. Most oral cancers are related to tobacco use, alcohol use (or both), or infection by the human papilloma virus (HPV).

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :

TEVA PHARMACEUTICALS INDUSTRIES LTD, MERCK & CO. INC., CIPLA INC., ELI-LILLY, FRESENIUS KABI AG, BRISTOL MAYERS SQUIBB COMPANY, SANOFI S.A, F-HOFFMANN-LA-ROCHE, VIATRIS INC. (MYLAN N.V), INTAS PHARMACEUTICALS LTD.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/15272

Severe COVID‐19 represents viral pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, which leads to acute respiratory distress syndrome. Its appearances can be viewed as a combination of the two processes that is viral pneumonia and acute respiratory distress syndrome. SARS‐CoV‐2 represents an ongoing worldwide threat, as this virus family has the potential to mutate and infect non‐immune population.

Furthermore, Owing to the well-known major risk factors, oral cancer is considered a preventable disease and moreover, due to easy accessibility, it can be detected in early stages. Yet, majority of oral cancer cases in the developing countries are diagnosed in advanced stages, resulting in increased morbidity and mortality of oral cancer. Generally, dentists play a pivotal role in the early detection of oral cancer through opportunistic screening when a patient presents in a dental practice for routine care and by rapid referral of suspicious lesions. In the time of COVID-19, nevertheless, the whole world being in lockdown, and dental clinics are closed. Therefore, opportunities for screening the oral cavity might be significantly disrupted, and consequently diagnosis of malignant and/or potentially malignant lesions might be delayed, a matter that inevitably leads to a missed diagnosis of oral cancer or, at best, diagnosis later on but at a late stage.

On the basis of drug therapy, the chemotherapy segment was the major shareholder 2020. In oral cancer, it’s usually used after surgery to prevent the cancer returning. In throat cancer, it’s often the first treatment to be given, in combination with chemotherapy medicine (chemoradiotherapy). The treatment is usually given every day over the course of 6 six weeks, depending on the size of the cancer and how far it has spread.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/15272

Increase in demand for surgical therapies for the treatment of oral cancer and rise in investment by governments in research & development to improve treatments boost the global market. North America dominated the global market in 2019 and this trend is projected to continue during the forecast period owing to the rising health care investments in the region and prevalence of oral cancer. The oral cancer treatment market in Asia-Pacific is anticipated to expand at a rapid pace during the forecast period. Rise in tobacco usage, increase in smoking, rapidly expanding health care industry, growing patient population, and high unmet needs are expected to drive the oral cancer treatment market in the region. Further, favorable government policies and rise in disposal income are anticipated to propel the oral cancer treatment market in the region during the forecast period.

𝐕𝐀𝐋𝐔𝐄 𝐏𝐑𝐎𝐏𝐎𝐒𝐈𝐓𝐈𝐎𝐍𝐒 𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐓𝐎 𝐓𝐇𝐄 𝐑𝐄𝐏𝐎𝐑𝐓:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com